Fig. 4: Association between pre-treatment immune parameters and FIGO stage. | Nature Communications

Fig. 4: Association between pre-treatment immune parameters and FIGO stage.

From: Neoadjuvant immune checkpoint blockade before chemoradiation for cervical squamous carcinoma (GINECO window-of-opportunity COLIBRI study): a phase II trial

Fig. 4: Association between pre-treatment immune parameters and FIGO stage.The alternative text for this image may have been generated using AI.

The 39 patients with mIF data at baseline were classified according to FIGO stage into FIGO I/II (n = 21) and FIGO III/IV (n = 18). A Graph depicting the P-values of selected tumor immune parameters between the two groups at baseline (Mann–Whitney U tests). B Boxplots of selected immune cell parameters. Source data are provided as a Source Data file. FIGO International Federation of Gynecology and Obstetrics, mIF multiplex-immunofluorescence, Teff T effector cells, Treg regulatory T cells.

Back to article page